- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02249806
Zürich Pulmonary Hypertension Outcome Assessment Cohort (ZHPHCohort)
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
PH is a serious disease with a dismal prognosis and impaired quality of life when left untreated. Advances in medical therapy have improved survival according to recent registries, but are associated with high healthcare costs. Most treatment trials and clinical follow-up assessments rely on the 6 minute walk distance as main outcome parameter although submaximal exercise performance reflects only one disease aspect.
Reliable patient centered and prognostically relevant outcome measures are highly warranted in the field of PH. With this prospective cohort study the investigator intend to gain important information on the course of the disease and knowledge on the value of different new and already established outcome parameters. New outcomes to be assessed will be home based activity monitoring, novel physiological measures, namely cerebral and muscle tissue oxygenation at rest and during exercise testing, stair ascent on mechanograph, sit to stand test and several serum markers and micro-RNA. All these assessments will be compared with hard endpoints events (death, lung-transplantation, hospitalization for PH), and with traditional outcome measures such as NYHA functional class, 6 minute walk distance, generic quality of life, cardiopulmonary exercise tests, sleep studies, health preference (utility) and cognitive function.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Contato de estudo
- Nome: Silvia Ulrich, MD
- Número de telefone: ++41442552220
- E-mail: pulmonalehypertonie@usz.ch
Estude backup de contato
- Nome: Isabel Schmied
- Número de telefone: ++41442552220
- E-mail: pulmonalehypertonie@usz.ch
Locais de estudo
-
-
-
Zurich, Suíça, 8091
- Recrutamento
- University Hospital Zurich
-
Contato:
- Silvia Ulrich, PD MD
- Número de telefone: 0041 44 255 22 20
- E-mail: silvia.ulrich@usz.ch
-
Investigador principal:
- Silvia Ulrich, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Patients with precapillary pulmonary hypertension
- Adult male and female patients of all ages referred to our center for evaluation/treatment of PH
- Written informed consent by the subject after information about the research project
Exclusion Criteria:
- Patients with severe concomitant left heart disease (left ventricular ejection fraction <40%).
- Patients with restrictive lung disease (FVC<60% predicted); obstructive lung disease (forced expiratory volume (FEV) <60% predicted, with FEV 1/FVC<70%).
- Patients with any other disease limiting their ability to move (skeletal disease, neurological disease, etc.)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Coorte
- Perspectivas de Tempo: Prospectivo
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
---|---|
PH target therapy
Patients receiving PH target therapy
|
Patients receiving PH target therapy
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Survival
Prazo: 10 years
|
Transplant free survival will be registered
|
10 years
|
Change in the 6 minute walk distance
Prazo: 10 years
|
The change in 6 minute walk distance will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
New York Heart association (NYHA) functional class
Prazo: 10 years
|
The change in NYHA class will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
Score in health related Quality of Life (HRQoL) questionnaires
Prazo: 10 years
|
The change in HRQoL class will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
Hemodynamic parameters by echocardiography
Prazo: 10 years
|
The change in echo parameters will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
Hospital days
Prazo: 10 years
|
Days spent in the hospital
|
10 years
|
red- and white blood cell counts
Prazo: 10 years
|
The change in blood cell count will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
Partial pressures of oxygen and carbon dioxide, pH, bicarbonate, electrolytes
Prazo: 10 years
|
The change in arterial blood gas parameters taken from radial artery will be registered at 3, 6, 12 months and yearly thereafter, (ABL '90Flex'-blood gas analyzer, Radiometer, Switzerland)
|
10 years
|
Score on Short-Form-6 D, Euro-Qol 5 D (EQ-5 D), visual analogue scale, time trade-off, standard gamble test
Prazo: 10 years
|
The change in utility will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
Overnight sleep study parameters
Prazo: 10 years
|
The change Overnight sleep study parameters will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
Score in cognitive function tests
Prazo: 10 years
|
The change cognitive function will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
Cardiopulmonary exercise test parameters
Prazo: 10 years
|
The change cardiopulmonary exercise test parameters will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
ECG parameters
Prazo: 10 years
|
The change in ECG parameters will be registered at 3, 6, 12 months and yearly thereafter
|
10 years
|
Motion, step counts, metabolic equivalent
Prazo: 10 years
|
The change in Activity assessment parameters will be registered at 3, 6, 12 months and yearly thereafter with actigraphy
|
10 years
|
Level of tissue oxygenation and blood volume index of prefrontal and quadriceps muscle tissue
Prazo: 10 years
|
Changes in cerebral and muscle tissue oxygenation will be assessed after 3, 6, 12 months and yearly thereafter by Near-infrared-Spectroscopy
|
10 years
|
Time, maximal power in stair-ascent test
Prazo: 10 years
|
Changes in performance of stair ascent test will be assessed after 3, 6, 12 months and yearly thereafter
|
10 years
|
Performance in Sit to stand test
Prazo: 10 years
|
Changes in sit- to stand test will be assessed after 3, 6, 12 months and yearly thereafter
|
10 years
|
Level of C-reactive protein (CRP)
Prazo: 10 years
|
The change in CRP will be registered at 3, 6, 12 months and yearly thereafter, taken from venous blood sample, measured by immunoassay ('Immulite 2000'; 'DPC'; Los Angeles; USA)
|
10 years
|
Level of N-terminal brain natriuretic peptide (BNP)
Prazo: 10 years
|
The change in BNP will be registered at 3, 6, 12 months and yearly thereafter, taken from venous blood sample, measured by Roche Modular Systems (Roche; Switzerland)
|
10 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Silvia Ulrich, MD, University Hospital Zurich, Department of Pulmonology
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2014-0214_ZH PH Cohort
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .